OpenLB
Open Library of Bioscience
Advanced Search
Journal of the European Academy of Dermatology and Venereology : JEADV
Apr, 2020;34 (4): 762-768.

Prognostic factors in patients with primary cutaneous anaplastic large cell lymphoma: a multicentric, retrospective analysis of the Spanish Group of Cutaneous Lymphoma.

R Fernández-de-Misa, B Hernández-Machín, A Combalía, M P García Muret, O Servitje, C Muniesa, F Gallardo, R M Pujol, R M Martí, A Ortiz-Brugués, L Maroñas-Jiménez, P L Ortiz-Romero, L Blanch Rius, R Izu, C Román, J Cañueto, M Blanes, M Morillo, J Bastida, Y Peñate, S Pérez Gala, P Espinosa Lara, A Pérez Gil, T Estrach
Author Information
  1. R Fernández-de-Misa: Department of Dermatology and Research Unit, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain. ORCID
  2. B Hernández-Machín: Department of Dermatology, Sefton Suite, DMC Healthcare, NHS Trust Liverpool, Liverpool, UK.
  3. A Combalía: Department of Dermatology, Hospital Clínico, University of Barcelona, Barcelona, Spain. ORCID
  4. M P García Muret: Department of Dermatology, Hospital Santa Creu i Sant Pau, UAB, Barcelona, Spain.
  5. O Servitje: Department of Dermatology, Hospital Universitari de Bellvitge, IDIBELL, Barcelona, Spain. ORCID
  6. C Muniesa: Department of Dermatology, Hospital Universitari de Bellvitge, IDIBELL, Barcelona, Spain.
  7. F Gallardo: Department of Dermatology, Hospital del Mar, Universitat Autónoma de Barcelona, Barcelona, Spain.
  8. R M Pujol: Department of Dermatology, Hospital del Mar, Universitat Autónoma de Barcelona, Barcelona, Spain.
  9. R M Martí: Department of Dermatology, Hospital Univeritari Arnau de Vilanova, IRBLleida, Lleida, Spain.
  10. A Ortiz-Brugués: Department of Dermatology, Hospital Univeritari Arnau de Vilanova, IRBLleida, Lleida, Spain.
  11. L Maroñas-Jiménez: Department of Dermatology, Hospital Universitario 12 de Octubre, i+12 Research Institute, Universidad Complutense, Madrid, Spain.
  12. P L Ortiz-Romero: Centre of Biomedical Research on Cancer (CIBERONC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
  13. L Blanch Rius: Department of Dermatology, Hospital de Basurto, Bilbao, Spain.
  14. R Izu: Department of Dermatology, Hospital de Basurto, Bilbao, Spain.
  15. C Román: Department of Dermatology, Hospital Universitario de Salamanca, Salamanca, Spain.
  16. J Cañueto: Department of Dermatology, Hospital Universitario de Salamanca, Salamanca, Spain.
  17. M Blanes: Department of Dermatology, Hospital General Universitario de Alicante, Alicante, Spain.
  18. M Morillo: Department of Dermatology, Hospital Universitario Virgen del Rocío, Sevilla, Spain.
  19. J Bastida: Department of Dermatology, Hospital Universitario Dr. Negrín, Las Palmas de Gran Canaria, Spain.
  20. Y Peñate: Department of Dermatology, Complejo Hospitalario Universitario Insular Materno-Infantil, Las Palmas de G.C, Spain.
  21. S Pérez Gala: Department of Dermatology, Hospital Universitario Ramón y Cajal, Madrid, Spain.
  22. P Espinosa Lara: Department of Dermatology, Hospital Universitario Infanta Cristina, Parla, Madrid, Spain.
  23. A Pérez Gil: Department of Dermatology, Hospital Virgen de Valme, Sevilla, Spain.
  24. T Estrach: Department of Dermatology, Hospital Clínico, IDIBAPS, University of Barcelona, Barcelona, Spain.
PMID: 31591786 DOI: 10.1111/jdv.16006

Abstract

BACKGROUND: Reliable prognostic factors for patients with primary cutaneous anaplastic large cell lymphoma (PCALCL) are lacking.
OBJECTIVE: To identify prognostic factors for specific survival in patients with PCALCL.
METHODS: Using the convenience sampling method, patients with PCALCL diagnosed from May 1986 to August 2017 in 16 University Departments were retrospectively reviewed.
RESULTS: One hundred eight patients were included (57 males). Median age at diagnosis was 58 years. All of them showed T1-3N0M0 stages. Seventy per cent of the cases presented with a solitary lesion, mostly at the limbs. Complete response rate after first-line treatment was 87%, and no advantage was observed for any of them (surgery, radiotherapy, chemotherapy or other approaches). Nodal and visceral progression rate was 11% and 2%, respectively. 5-year specific survival (SSV) reached 93%; 97% for T1 patients and 84% for T2/T3 patients (P = 0.031). Five-year SSV for patients developing early cutaneous relapse was 64%; for those with late or no relapse, 96% (P = 0.001). Estimated median SSV for patients showing nodal progression was 103 months (95% CI: 51-155 months); for patients without nodal progression, estimated SSV did not reach the median (P < 0.001). Nodal progression was an independent predictive parameter for shorter survival (P = 0.011).
CONCLUSION: Multiple cutaneous lesions at presentation, early skin relapse and nodal progression portrait worse prognosis in patients with PCALCL.

References

Willemze R, Jaffe ES, Burg G et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105: 3768-3785.
Penate Y, Servitje O, Machan S et al. The first year of the AEVD primary cutaneous lymphoma registry. Actas Dermosifiliogr 2018; 109: 610-616.
Kempf W. Cutaneous CD30-positive lymphoproliferative disorders. Surg Pathol Clin 2014; 7: 203-228.
Benner MF, Willemze R. Applicability and prognostic value of the new TNM classification system in 135 patients with primary cutaneous anaplastic large cell lymphoma. Arch Dermatol 2009; 145: 1399-1404.
Woo DK, Jones CR, Vanoli-Storz MN et al. Prognostic factors in primary cutaneous anaplastic large cell lymphoma: characterization of clinical subset with worse outcome. Arch Dermatol 2009; 145: 667-674.
Kim YH, Willemze R, Pimpinelli N et al. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110: 479-484.
Kempf W, Pfaltz K, Vermeer MH et al. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood 2011; 118: 4024-4035.
Bekkenk MW, Geelen FA, van Voorst Vader PC et al. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood 2000; 95: 3653-3661.
Kempf W, Kerl K, Mitteldorf C. Cutaneous CD30-positive T-cell lymphoproliferative disorders-clinical and histopathologic features, differential diagnosis, and treatment. Semin Cutan Med Surg 2018; 37: 24-29.
Bekkenk MW, Kluin PM, Jansen PM, Meijer CJ, Willemze R. Lymphomatoid papulosis with a natural killer-cell phenotype. Br J Dermatol 2001; 145: 318-322.
Paulli M, Berti E, Rosso R et al. CD30/Ki-1-positive lymphoproliferative disorders of the skin-clinicopathologic correlation and statistical analysis of 86 cases: a multicentric study from the European Organization for Research and Treatment of Cancer Cutaneous Lymphoma Project Group. J Clin Oncol 1995; 13: 1343-1354.
Liu HL, Hoppe RT, Kohler S, Harvell JD, Reddy S, Kim YH. CD30 + cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. J Am Acad Dermatol 2003; 49: 1049-1058.
Hughey LC. Practical management of CD30(+) lymphoproliferative disorders. Dermatol Clin 2015; 33: 819-833.
Melchers RC, Willemze R, Daniels LA et al. Recommendations for the optimal radiation dose in patients with primary cutaneous anaplastic large cell lymphoma: a report of The Dutch Cutaneous Lymphoma Group. Int J Radiat Oncol Biol Phys 2017; 99: 1279-1285.
Prince HM, Kim YH, Horwitz SM et al. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet 2017; 390: 555-566.
Casulo C, Byrtek M, Dawson KL et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the national lymphocare study. J Clin Oncol 2015; 33: 2516-2522.
Prieto-Torres L, Rodriguez-Pinilla SM, Onaindia A, Ara M, Requena L, Piris MA. CD30-positive primary cutaneous lymphoproliferative disorders: molecular alterations and targeted therapies. Haematologica 2019; 104: 226-235.
Yu JB, Blitzblau RC, Decker RH, Housman DM, Wilson LD. Analysis of primary CD30 + cutaneous lymphoproliferative disease and survival from the Surveillance, Epidemiology, and End Results database. J Clin Oncol 2008; 26: 1483-1488.

MeSH Term

Disease Progression
Female
Humans
Lymphatic Metastasis
Lymphoma, Primary Cutaneous Anaplastic Large Cell
Male
Middle Aged
Neoplasm Staging
Prognosis
Retrospective Studies
Spain
Survival Rate
Journal Article Multicenter Study

Word Cloud

Similar Articles

Cited By